Publication

Article

Pharmacy Times

Volume00

Economic Model Reveals Best Therapies

A joint study from UCLA and the Veterans Affairs Greater Los Angeles Healthcare Systemfound that the combination of a common nonsteroidal anti-inflammatory drug (NSAID) and anacid-lowering drug is both cost-effective and treatment-effective. The study team compared 3 therapiesfor treating arthritis: (1) an NSAID, such as ibuprofen or naproxen; (2) an NSAID with anacid-reducer (proton pump inhibitor; PPI), such as lansoprazole (Prevacid) or esomeprazole magnesium(Nexium); and (3) a cyclooxygenase-2 (COX-2) inhibitor, such as rofecoxib (Vioxx) orcelecoxib (Celebrex).

The results showed that, for high-risk patients, an OTC NSAID used with a PPI was the safestand most cost-effective treatment. Study author Dr. Brennan Spiegel, codirector of the Center forthe Study of Digestive Healthcare Quality and Outcomes, remarked, "COX-2 inhibitors were nota health economic bargain at all-especially given the added costs of more heart attacks."

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs